Le Lézard
Classified in: Health
Subject: TRI

Innovative Alzheimer's Treatment from China Concludes Phase 3 Clinical Trials


SHANGHAI, July 19, 2018 /PRNewswire/ --  Shanghai Green Valley Pharmaceutical Co., Ltd. (Green Valley) today announced that its Phase 3 Study of Sodium Oligomannurarate (GV-971) Capsules on mild-to-moderate Alzheimer's disease met its primary endpoint.

This randomized, double-blinded and placebo-controlled clinical trial in China aimed to evaluate safety and efficacy of GV-971, a multi-targeting oligosaccharide drug, on study participants with mild-to-moderate Alzheimer's disease (MMSE score ranged from 11 to 26). Subjects took 450mg GV-971 orally twice each day for 36 weeks. The primary endpoint showed the improved change of the Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) score after the 36 week GV-971 treatment compared to the placebo control. GV-971 showed a similar profile to that of the placebo, no amyloid-related imaging abnormalities (ARIA) were observed.

Alzheimer's disease is a chronic neurodegenerative disorder characterized by a progressive loss of cognitive function. According to Alzheimer's Disease International, there are approximately 48 million patients world-wide with Alzheimer's disease, and this number is expected to reach 130 million by 2050 due to a rapid growth of the aging population.

Green Valley plans to submit the marketing authorization application of GV-971 for treatment of mild-to-moderate Alzheimer's disease to the China National Drug Administration later this year.

SOURCE Shanghai Green Valley Pharmaceutical Co., Ltd


These press releases may also interest you

at 16:19
Unifor eyes SEIU-CUPE award for Ontario health care members
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...

at 15:55
Valley Mountain Regional Center Provides Notice Following Data Security Incident
Valley Mountain Regional Center ("VMRC") experienced a data security incident that involved personal and / or protected health information belonging to certain current and former patients and has provided notice of this incident to impacted...

at 15:44
Federal Court Rules CVS Acted With "Deliberate Indifference" When It Adopted Rx Program That Discriminates Against People Living With HIV, Says Consumer Watchdog
Late yesterday the United States District Court for the Northern California ruled that CVS acted intentionally under the "deliberate indifference" standard when it implemented a drug program that discriminates against people living with HIV....

at 15:33
Alameda Health System Needs Immediate Assistance with Patient Identification
Alameda Health System needs help identifying a patient who arrived at the Wilma Chan Highland Hospital Campus on March 15, 2024, without identification....

More news about Health...


News published on and distributed by: